Skip to main content
Erschienen in: The Patient - Patient-Centered Outcomes Research 1/2014

01.03.2014 | Original Research Article

Walking Speed and Health‐Related Quality of Life in Multiple Sclerosis

verfasst von: Christine G. Kohn, William L. Baker, Matthew F. Sidovar, Craig I. Coleman

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to evaluate the association between slower walking and health-related quality of life (HRQoL) in multiple sclerosis (MS) patients.

Methods

We used North American Research Committee on Multiple Sclerosis data to conduct a study of participants completing both the regular semiannual and supplemental spring 2010 surveys. Question 10 of the 12-item Multiple Sclerosis Walking Scale (“How much has your MS slowed down your walking?”) was used to assess patient-perceived impact of walking speed on HRQoL. HRQoL assessments included the Short Form-12 (SF-12), EuroQoL-5 Dimension (EQ-5D), Short Form-6 Dimension (SF-6D), and a visual analog scale (VAS).

Results

A total of 3,670 registrants completed both surveys and were included. Unadjusted analyses showed that compared with those classifying the impact of MS on walking speed as “not at all” (n = 661), participants stating MS impacted their walking speed “a little” (n = 722), “moderately” (n = 486), “quite a bit” (n = 714), and “extremely” (n = 1,087) reported poorer SF-12 physical component scale (PCS) (r = −0.69, p < 0.001), mental component scale (MCS) (r = −0.16, p < 0.001), and health status index scores (r = −0.50 to −0.51 for the EQ-VAS, EQ-5D and SF-6D, p < 0.001 for all). After adjustment for demographics and additional MS-related disability and symptoms, the impact of walking speed remained significant, although less profound for the PCS (reductions of 3.59–12.31 across walking speed classifications) and index scores (reductions ranging from 1.98 to 14.06, 0.04 to 0.13, and 0.02 to 0.07 for the EQ-VAS, EQ-5D, and SF-6D). Reduction in walking speed was no longer associated with a worse MCS (p > 0.05 all classifications of walking speed).

Conclusion

Incremental decrements in HRQoL were observed as patients perceived greater levels of reduction in their walking speed.
Literatur
1.
Zurück zum Zitat Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696–702.PubMedCrossRef Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696–702.PubMedCrossRef
2.
Zurück zum Zitat Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76:58–63.PubMedCrossRef Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76:58–63.PubMedCrossRef
3.
Zurück zum Zitat Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319–24.PubMed Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319–24.PubMed
4.
Zurück zum Zitat Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm. 2007;30:233–67.PubMed Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm. 2007;30:233–67.PubMed
6.
Zurück zum Zitat Jeffery D, Kirzinger S, Halper J, et al. Health-related quality of life, EDSS and Timed 25-Foot Walk in a multiple sclerosis population of a real-world observational outcomes study: baseline data from ROBUST. Value Health. 2009;12:A372. Jeffery D, Kirzinger S, Halper J, et al. Health-related quality of life, EDSS and Timed 25-Foot Walk in a multiple sclerosis population of a real-world observational outcomes study: baseline data from ROBUST. Value Health. 2009;12:A372.
7.
Zurück zum Zitat Robinson D Jr, Zhao N, Gathany T, et al. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial. Curr Med Res Opin. 2009;25:1121–30.PubMedCrossRef Robinson D Jr, Zhao N, Gathany T, et al. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial. Curr Med Res Opin. 2009;25:1121–30.PubMedCrossRef
8.
Zurück zum Zitat Hoogervorst EL, Zwemmer JN, Jelles B, et al. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler. 2004;10(5):569–74.PubMedCrossRef Hoogervorst EL, Zwemmer JN, Jelles B, et al. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler. 2004;10(5):569–74.PubMedCrossRef
9.
Zurück zum Zitat Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.PubMedCentralPubMedCrossRef Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Miller DM, Cohen JA, Kooijmans M, et al. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Mult Scler. 2006;12:180–6.PubMedCrossRef Miller DM, Cohen JA, Kooijmans M, et al. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Mult Scler. 2006;12:180–6.PubMedCrossRef
11.
Zurück zum Zitat O’Connor P, Lee L, Ng PT, et al. Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology. 2001;57:889–91.PubMedCrossRef O’Connor P, Lee L, Ng PT, et al. Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology. 2001;57:889–91.PubMedCrossRef
13.
Zurück zum Zitat Hobart JC, Riaza A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Neurology. 2003;60:31–6.PubMedCrossRef Hobart JC, Riaza A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Neurology. 2003;60:31–6.PubMedCrossRef
14.
Zurück zum Zitat Ware JE Jr, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12® Health Survey (with a supplement documenting version 1). Lincoln: Quality Metric Incorporated; 2002. Ware JE Jr, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12® Health Survey (with a supplement documenting version 1). Lincoln: Quality Metric Incorporated; 2002.
15.
Zurück zum Zitat The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef
16.
Zurück zum Zitat Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851–9.PubMedCrossRef Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851–9.PubMedCrossRef
17.
Zurück zum Zitat Taylor R. Interpretation of the correlation coefficient: a basic review. JDMS. 1990;1:35–9. Taylor R. Interpretation of the correlation coefficient: a basic review. JDMS. 1990;1:35–9.
18.
Zurück zum Zitat Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007;13:1176–82.PubMedCrossRef Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007;13:1176–82.PubMedCrossRef
19.
Zurück zum Zitat Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18:914–24.PubMedCrossRef Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18:914–24.PubMedCrossRef
Metadaten
Titel
Walking Speed and Health‐Related Quality of Life in Multiple Sclerosis
verfasst von
Christine G. Kohn
William L. Baker
Matthew F. Sidovar
Craig I. Coleman
Publikationsdatum
01.03.2014
Verlag
Springer International Publishing
Erschienen in
The Patient - Patient-Centered Outcomes Research / Ausgabe 1/2014
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-013-0028-x

Weitere Artikel der Ausgabe 1/2014

The Patient - Patient-Centered Outcomes Research 1/2014 Zur Ausgabe